DiaMedica Therapeutics (DMAC) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 21.1% versus a gain of 15.0%. Over five years, DMAC leads with a +88.3% price change compared with +13.9% for FENC. DiaMedica Therapeutics is the larger company by market cap ($408.2 million vs $350.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DMAC | FENC |
|---|---|---|
| Share price | $7.57 | $9.98 |
| Market cap | $408.22M | $349.97M |
| 1-day change | -5.85% | -3.57% |
| YTD return | -4.90% | +29.61% |
| 1-year return | +15.05% | +21.12% |
| 5-year return | +88.31% | +13.93% |
| Forward P/E | — | 10.53 |
| EPS (TTM) | $-0.72 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $44.64M |
| Revenue growth (YoY) | — | -6.09% |
| Net income (latest FY) | $-32.77M | $-9.74M |
| Operating margin | — | -14.07% |
| Net margin | — | -21.82% |
| 52-week high | $10.42 | $13.25 |
| 52-week low | $5.25 | $5.65 |
| Distance from 52-week high | -27.35% | -24.68% |
| Analyst consensus | none | none |
| Avg. price target upside | +104.76% | +77.05% |
| Average volume | 182.81K | 188.89K |
| Shares outstanding | 53.93M | 35.07M |
| Employees | 35 | 35 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Healthcare · Biotechnology · 35 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Healthcare · Biotechnology · 35 employees
DMAC vs FENC FAQ
Which is bigger, DiaMedica Therapeutics or Fennec Pharmaceuticals?
DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $408.22M compared with $349.97M for Fennec Pharmaceuticals (FENC).
Which stock has performed better over the past year, DMAC or FENC?
FENC returned +21.12% over the past 12 months, compared with +15.05% for DMAC (price return, excluding dividends). Past performance does not predict future results.
Are DiaMedica Therapeutics and Fennec Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.